CAR-T treatment for CD70-positive advanced solid tumors
Part of Cancer clinical trials.
This Phase 1/2 trial tests a lab-made immune therapy (CAR-T) designed to attack cancers that have a protein called CD70. It may help people whose solid tumor has not responded to standard treatment, but it also requires specific lab confirmation and careful health screening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 75, and you expect to live more than 3 months.
- Your cancer is an advanced or metastatic solid tumor and has failed standard first treatment (or has no standard option).
- Your tumor must be CD70-positive, with enough CD70 protein level (at least 30% on testing).
- You must have at least one measurable tumor spot that can be tracked on scans.
- You can provide a fresh or stored tumor tissue sample (from the last 6 months) and agree to possible repeat biopsy.
- Your blood counts and organ tests (liver, kidneys, etc.) must be strong enough for treatment, and you must have a good enough energy level (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This trial is testing a new CAR-T cell therapy given as an injection for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. CAR-T therapy uses your own immune cells to target and attack cancer cells. It may be an option if you have tried other treatments and they are no longer working.
This phase 1 trial tests a new way to use your own immune cells to fight advanced solid tumors. The treatment is given directly into the tumor. It is for people who have run out of standard treatment options.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.